The ability of Nucleinat in the complex therapy of a bronchial asthma to reduce the content of interleukins -4, -5 and -8 in the blood serum was analyzed by the double-blind placebo-controlled method in 98 school age children. Two clinical groups were formed with the help of the accidental numbers table. The application of the Nucleinat in the complex anti-inflammatory therapy of BA was accompanied by increasing risk of lower content in blood serum of interleukins -4, -5 and -8 at the expense of possible reduction of inflammatory process in bronchi. The usage of Nucleinat in the basic therapy of BA in school-age children significantly reduced the risks of high IL-8 content in the blood serum: DAR — 93.2%, DRR — 65.3% (95% CI 55.1–74.5) MNT — 1.5 (95% CI 0,1–6,3).
